Voleon Capital Management LP Decreases Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Voleon Capital Management LP reduced its stake in Johnson & Johnson by 1.5%, selling 1,710 shares to hold a total of 111,747 shares, which are now valued at approximately $18.5 million.
• Johnson & Johnson's quarterly earnings report showed $2.77 earnings per share, exceeding expectations, while its revenue reached $23.74 billion, up 5.8% from the same quarter last year.
• The company announced a quarterly dividend of $1.30 per share, which represents an annualized rate of $5.20 and a dividend yield of 2.9%, with a payout ratio of 55.61%.

Voleon Capital Management LP trimmed its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 1.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 111,747 shares of the company's stock after selling 1,710 shares during the period. Johnson & Johnson makes up 1.5% of Voleon Capital Management LP's portfolio, making the stock its 7th biggest holding. Voleon Capital Management LP's holdings in Johnson & Johnson were worth $18,532,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Highline Wealth Partners LLC boosted its holdings in Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the period. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $49,000. Finally, Capital A Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $50,000. 69.55% of the stock is currently owned by institutional investors.

Insider Activity at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Shares of NYSE JNJ traded down $0.13 during mid-day trading on Monday, hitting $178.30. 8,325,117 shares of the stock were exchanged, compared to its average volume of 7,659,331. The company has a market cap of $429.40 billion, a P/E ratio of 19.07, a PEG ratio of 2.27 and a beta of 0.40. The stock's fifty day simple moving average is $169.09 and its two-hundred day simple moving average is $160.90. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. During the same quarter last year, the business posted $2.82 earnings per share. The company's revenue was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is 55.61%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Wall Street Zen lowered shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Friday. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Guggenheim reaffirmed a "neutral" rating and set a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Citigroup upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Thursday, August 21st. Finally, Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.